E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute Myeloid Leukemia |
Leucemia mieloide aguda |
|
E.1.1.1 | Medical condition in easily understood language |
Acute Myeloid Leukemia |
Leucemia mieloide aguda |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000886 |
E.1.2 | Term | Acute myeloid leukemia |
E.1.2 | System Organ Class | 100000012984 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of the addition of inecalcitol to decitabine treatment on overall survival in previously untreated AML patients 65 years or more who are randomly assigned to receive decitabine with or without inecalcitol. |
Evaluar el efecto de añadir inecalcitol al tratamiento con decitabina en la supervivencia global de pacientes con leucemia mieloide aguda previamente no tratados, de 65 años o más, aleatoriamente seleccionados para recibir decitabina con o sin inecalcitol. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate: - Complete response - Event-free and relapse-free survival between treatment arms - Incidence and severity of toxicities - Incidence of infectious episodes |
Evaluar: - La respuesta completa - La supervivencia libre de evento y la supervivencia libre de recaída entre grupos de tratamiento - La incidencia y la gravedad de la toxicidad - La incidencia de episodios infecciosos |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Patients aged 65 to < 75 years with at least one non severe comorbidity ie disease or syndrome with mild to moderate clinical or diagnostic observations or lab abnormalities which could increase the risk of toxicity and/or early death of intensive chemotherapy in the opinion of the investigator and are not contra-indicated for non-intensive chemotherapy. (examples provided in section 5.3) or ≥ 75 years with or without any comorbidity at the time of the informed consent signature; •Newly diagnosed, untreated de novo or secondary AML according to WHO classification; •Fertile men agree to practice effective contraception during the study and for 3 months following treatment discontinuation; •Patients agree to comply with the study requirements and agrees to come to the clinic for required study visits; •Patients agree to follow medication restrictions during the study; •Patients have signed written informed consent. |
•Pacientes de entre 65 a < 75 años con al menos una comorbilidad no severa, por ejemplo enfermedad o síndrome con observaciones de leves a moderadas clínicas o de diagnóstico, o anomalías de laboratorio que pudieran aumentar el riesgo de toxicidad y/o muerte prematura por quimioterapia intensiva según la opinión del investigador y que no están contraindicados para una quimioterapia no intensiva (en la sección 5.3 se exponen ejemplos). o ≥ 75 años con o sin ninguna comorbilidad en el momento de la firma del consentimiento informado; •Leucemia mieloide aguda de reciente diagnóstico, no tratada de novo o secundaria según la clasificación de la OMS; •Los hombres fértiles aceptan la práctica de una anticoncepción eficaz durante el estudio y durante los tres meses siguientes a la interrupción del tratamiento; •Los pacientes aceptan cumplir los requisitos del estudio y acudir a la clínica para las visitas que exige el estudio; •Los pacientes aceptan seguir las restricciones de medicación durante el estudio; •Los pacientes han firmado un consentimiento informado escrito. |
|
E.4 | Principal exclusion criteria |
•Prior or current treatment with chemotherapy for any myeloid disorder (excluding hydroxyurea) or radiotherapy for extramedullary involvement within 2 weeks of randomization; •Prior treatment with decitabine, azacitidine, or cytarabine; •Chronic myelogenous or acute promyelocytic leukaemia; •Prior malignancies for 5 years with exception of basal cell, squamous cell carcinoma of the skin, or carcinoma « in situ » of the cervix or breast; •Known CNS involvement; •Patient eligible to bone marrow or stem cell transplant; •WBC ≥ 30.000/mm3; •Impaired renal function with Creatinine clearance < 30 mL/min/1.73m², according to the MDRD formula; •Serum bilirubin ≥ 2.5 x ULN and/or AST and/or ALT ≥ 2.5 x ULN (upper limit of normal value); •Calcemia ≥ 2.65 mmol/L (106 mg/L) at screening assessment (corrected with albuminemia); •History of diseases known to be associated with calcium disorders: ongoing hyperparathyroidism, sarcoidosis….; •Presence or history of symptomatic kidney stones in the last 5 years; •Hypersensitivity to any of the excipients of decitabine (Potassium dihydrogen phosphate (E340) ; Sodium hydroxide (E524) ; Hydrochloric acid (for pH adjustment) or to the excipient of inecalcitol tablets (lactose); •Current use of drugs known to influence serum calcium (such as thiazide diuretics, teriparatide, calcitonin and multivitamin supplements containing > 400 IU of vitamin D or calcium); •Current use of digitalis; •Current use of drugs which could influence bioavailability of inecalcitol (such as magnesium-containing antacids, bile-resin binders); •Use of any other experimental drug or therapy or vitamin D supplementation within 4 weeks of randomization; •Known HIV; •Patients who are eligible for intensive induction therapy with curative intent; •Refractory congestive heart failure; •Active infection resistant to anti-infective therapy; •Documented pulmonary disease with DLCO ≤ 65% or FEV1 ≤ 65%, or dyspnea at rest or requiring oxygen, or any pleural neoplasm or uncontrolled lung neoplasm; • Liver cirrhosis Child B or C or acute viral hepatitis; • Current mental illness requiring psychiatric hospitalization, institutionalization or intensive outpatient management, or current cognitive status that produces dependence (as confirmed by the specialist) not controlled by the caregiver; • Uncontrolled neoplasia. |
•Tratamiento previo o actual con quimioterapia para cualquier trastorno mieloide (salvo hidroxiurea) o con radioterapia para afecciones extramedulares en las dos semanas previas a la aleatorización; •Tratamiento previo con decitabina, azacitidina o citarabina; •Neoplasias previas durante 5 años con excepción de carcinoma de células basales o escamosas de la piel, o carcinoma "in situ" de la cérvix o de mama; •Leucemia mieloide crónica o leucemia promielocítica aguda; •Afección conocida del sistema nervioso central; •Paciente apto para trasplante de médula ósea o de célula madre; •Recuento de leucocitos ≥ 30.000/mm3; •Insuficiencia renal con aclaramiento de creatinina < 30 mL/min/1,73m² según la fórmula de Modificación de Dieta en la Enfermedad Renal; •Bilirrubina sérica ≥ 2,5 x límite superior normal y/o transaminasas AST y/o ALT ≥ 2,5 x límite superior normal; •Calcemia ≥ 2,65 mmol/L (106 mg/L) en la evaluación de la vista de selección (corregida con albuminemia); •Antecedentes de enfermedades conocidas por su asociación con trastornos del calcio: hiperparatiroidismo en curso, sarcoidosis; •Presencia o antecedentes de cálculos renales sintomáticos en los últimos 5 años; •Hipersensibilidad a algunos de los excipientes de la decitabina (dihidrogenofosfato de potasio (E340); hidróxido sódico (E524); ácido clorhídrico (para ajuste del pH) o al excipiente de los comprimidos de inecalcitol (lactosa); •Consumo actual de medicamentos conocidos por influir en el calcio sérico (como los diuréticos tiazídicos, la teriparatida, la calcitonina y los suplementos multivitamínicos con > 400 unidades internacionales de vitamina D o calcio); •Consumo actual de digitalis; •Consumo actual de medicamentos que podrían influir en la biodisponibilidad del inecalcitol (antiácidos con magnesio, resinas secuestradoras); •Consumo de cualquier otro medicamento o terapia experimental o suplementos de vitamina D en las 4 semanas previas a la aleatorización; •VIH conocido; •Pacientes aptos para terapia de inducción intensiva con intención curativa; •Insuficiencia cardíaca congestiva refractaria; •Infección activa resistente a tratamiento antiinfeccioso; •Enfermedad pulmonar documentada con capacidad de difusión (DLCO) ≤ 65%, o volumen máximo de aire espirado en el primer segundo (FEV1) ≤ 65%, o disnea en reposo o que requiera oxígeno, o cualquier neoplasia pleural o neoplasia pulmonar no controlada; •Cirrosis hepática Child-Pugh B o C, o hepatitis viral aguda; •Enfermedad mental actual que requiera hospitalización psiquiátrica, internamiento o tratamiento intensivo ambulatorio, o estado cognitivo actual que produzca dependencia (confirmada por especialistas) no controlada por el cuidador; •Neoplasia no controlada. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall survival defined as the time from randomization to the date of death for any cause |
Supervivencia global definida como el periodo comprendido entre la aleatorización y la fecha de muerte por cualquier causa |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Each time during the study. |
A lo largo de todo el estudio |
|
E.5.2 | Secondary end point(s) |
Efficacy: - Proportion of patients who obtain composite CR according to IWG 2003 recommendations including CRi/CRp; - Event-free survival defined as the time from the date of randomization to the date of treatment failure, relapse or death from any cause, whichever occurs first. - Relapse-free survival is defined only for patients achieving a complete remission. It is defined as the interval from the date of first documentation of leukemia-free state to the date of treatment failure, relapse or death from any cause whichever occurs first
Safety: - Incidence and characteristics of all AE(s) and SAE(s) from clinical and laboratory assessment according to the NCI/CTC AE version 4.0 scale. - Incidence, severity, duration and time to occurrence of hypercalcemia. |
Eficacia: - Proporción de pacientes que obtienen una respuesta completa compuesta según las recomendaciones del Grupo de Trabajo Internacional (IWG 2003), incluyendo CRi/CRp; - Supervivencia libre de evento definida como el periodo comprendido entre la aleatorización y la fecha de fallo del tratamiento, recaída o muerte por cualquier causa, lo primero que suceda. - La supervivencia libre de recaída sólo se define para pacientes que consiguen una remisión completa. Se define como el intervalo desde la primera fecha en que se documente el estado sin leucemia hasta la fecha de fallo del tratamiento, recaída o muerte por cualquier causa, lo primero que suceda.
Seguridad: - Incidencia y características de todos los acontecimientos adversos y acontecimientos adversos graves según valoración clínica y de laboratorio conforme a la escala de criterios de toxicidad NCI/CTC AE, versión 4.0. - Incidencia, gravedad, duración y tiempo hasta que se produce la hipercalcemia. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Efficacy : after 3 and 6 cycles of treatment - Safety : continuously from informed consent form signature and up to 4 weeks after the last IMP intake. |
- Eficacia : tras 3 y 6 ciclos de tratamiento - Seguridad : de forma continua desde la firma del consentimiento informado y hasta 4 semanas tras la última dosis de tratamiento de estudio. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
France |
Germany |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |